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INTRODUCTION:
• HNRNPU is a is a highly conserved protein responsible for
assisting spliceosomes in mediating transcription and
alternative splicing activity.
• HNRNPU has been involved in neurodevelopmental and
neurodegenerative diseases.
• Recently, Durkin et al (PMID: 32319732) reported 21
previously unreported probands with variable presentation,
but usually with hypotonia, global developmental delays, and
seizures [1].
• We describe a patient with a history of BRUE and mild unique
facial features who was identified to have a pathogenic de
novo nonsense mutation in HNRNPU (c.803+2T>C; p. ?). The
variants are listed in Table 1.

Pertinent Physical Findings
Facial/Physical Characteristics: Telecanthus, broad nasal bridge, and short
palpebral fissures. Additionally, a single transverse palmar crease (right hand).

CLINICAL COURSE:
•

PREGNANCY HISTORY: A choroid plexus cyst was identified
on a 20-week anatomy scan but resolved by 28 weeks. NIPT
was negative.

•

DEVELOPMENTAL HISTORY: Gross motor skills were delayed
about 6 months. He was able to sit by himself at 14 months, pull
up to stand at 18 months, cruise at 20 months and walk at 20
months. At 2 years old, he was babbling and speaking 5-10
words. He communicated with hand gestures and could
understand simple directions. He was responding to his name
being called.

•

FIRST ADMISSION (4 months old): Admitted following first
apneic spell.
•
Imaging including CT, MRI, CXR, ENT, Holter monitor,
and Echo. Apnea was determined to be due to
gastroesophageal reflux (by exclusion).
•
He started on reflux medications at 6 months of age,
which helped prevent future episodes. He had no further
episodes until he was taken off medication at 18 months
old, resulting in restarting the reflux medication.
•
At his 4-month inpatient stat, an episode was captured
on video EEG, but without EEG correlate. Our patient
was started on an AED and placed on 1.5 ml PO BID
(150 mg) of Keppra (Levetiracetam), to go along with his
normal bacitracin (topical – BID) and famotidine (dosing
weight, oral – every 12 hrs).

•

Additional apneic events occurred at 6, 18, 25, and 26 months.

•

SECOND ADMISSION (28 months old): Admitted due to recurrent apneic spells and global developmental delay. Genetics
was consulted. The latest episode at 26 and 28 months
involved multiple apneic spells within a short period of time.

Cardiovascular: Extensive history of tachycardia with apneic and
acrocyanotic spells, with first onset at 4 months. Apneic events reoccurred at 6,
18, 25, and 26 months of life. These apneic spells usually occurred within 30
minutes of feeding. During these spells, our patient becomes completely limp and
appears unconscious. Atrial septal defect, sinus rhythm with intermittent 1st degree
AV block, blocked premature atrial contractions, left axis deviation, right bundle
branch block, and a Left Ventricular Ejection Fraction of 67%, small secundum
atrial septal defect (ASD) with small left-to-right shunting.
Neurological: Global developmental delay, hypotonia, dyspraxia with cognitive
disability, T2/FLAIR hyperintense signal in the white matter of the parietal lobes,
left greater than right (could be due to incomplete myelination in this region),
generalized slowing indicative of a mild nonspecific encephalopathy, partial onset
seizures with eye opening.
Gastrointestinal: Feeding aversion history with history of significant reflux.

Table 1: Chromosomal Sequencing Analysis (20,095 Gene Panel; gene sequencing with
deletion and duplication analysis; genome-wide copy number analysis; TRIO).

DISCUSSION / CONCLUSIONS
Genetic testing including microarray and sequencing studies revealed the variants in Table 1. No genomic dosage anomalies were reported. The
truncating de novo (c.803+2T>C) variant in HNRNPU was classified as likely pathogenic. This variant may disrupt the canonical splice donor site for exon 2 and
while this mutation in novel, other canonical splice disrupting variants have been reported to be pathogenic. hnRNPs have a key role in mediating transcription,
alternative splicing, and translation activity. Alternative splicing can lead to an increase in proteomic diversity. This is necessary for the flexibility of a cancerous
cell to respond to various environments. There is little research surrounding hnRNP-U and its role in cancer development, but the production of alternative
transcripts due to dysregulation can lead to aberrant protein isoforms with altered functions [2]. Regarding neurodegenerative diseases, hnRNPs are responsible
for the regulation of translation at the presynaptic sites as well as the transportation of stabilized mRNAs along the axonal cytoskeleton to these presynaptic
translation hubs. Deviation from hnRNPs’ normal function can result in multiple neurological diseases, such as ALS/FTLD, SMA and AD [3]. The role of hnRNP-U
in neurodegenerative diseases is not fully understood, yet it commonly presents in neurodegenerative diseases.
As more is learned, the roles of hnRNPs in other diseases will also be discovered. Understanding the roles of hnRNPs in diseases will be beneficial for developing
potential therapeutic targets. For example, RNA-mediated toxicity is a hallmark of many affected neurons in neurodegenerative diseases like ALS/FTLD [4].
Hopefully future targeted antibody therapy towards these RNA foci, can attenuate this RNA toxicity. This targeted RNA-based therapy will be a critical step in
reducing the expression level of the disease-propagating proteins. This suggests the addition of HNRNPU to all seizure-related diagnostic panels. We would also
recommend including the HNRNPU-related disorders in a differential diagnosis of BRUE and recurrent apneic episodes as any underlying clonic activity may be
profoundly subtle.
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